Logo

Genentech’s Crenezumab Fails to Meet Primary Endpoints in Alzheimer’s Disease with Cognitively Unimpaired Patients

Share this

Genentech’s Crenezumab Fails to Meet Primary Endpoints in Alzheimer’s Disease with Cognitively Unimpaired Patients

Shots:

  • The study was evaluating the potential of crenezumab to slow or prevent Alzheimer’s disease in cognitively unimpaired patients who carry the Presenilin 1 E280A mutation. The data will be presented at the AAIC in Aug 2022
  • The study did not show significant clinical benefit in 1EPs i.e, assessing the rate of change in cognitive abilities or episodic memory function, measured by the API ADAD composite cognitive score & the Free and Cued Selective Reminding Test (FCSRT) Cueing Index
  • The study API ADAD (Colombia) enrolled 252 people of which two-thirds participants carried a specific mutation which causes cognitive impairment. Participants were randomized to receive crenezumab or PBO over 5 to 8yrs. The study was supported by the National Institute on Aging, generous philanthropic contributions to Banner Alzheimer’s Foundation

Ref: Businesswire | Image: Genentech

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions